PLOS ONE: MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells
c-Met inhibitor - Wikipedia
Mechanisms of resistance to single-agent MET TKIs in the... | Download Scientific Diagram
HER3 and mutant EGFR meet MET | Nature Medicine
Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro - Journal of Thoracic Oncology
MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregula | OTT
MET amplification causes EGFR-TKI resistance by activating... | Download Scientific Diagram
The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy - Lung Cancer
Multiplex RNA‐based detection of clinically relevant MET alterations in advanced non‐small cell lung cancer - Aguado - 2021 - Molecular Oncology - Wiley Online Library
Mechanisms of resistance to EGFR tyrosine kinase inhibitors - ScienceDirect
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - Cancer Treatment Reviews
Liquid biopsy uncovers distinct patterns of DNA methylation and copy number changes in NSCLC patients with different EGFR-TKI resistant mutations | Scientific Reports
Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer? | Semantic Scholar
AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activation - Lung Cancer
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
PLOS ONE: MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells
Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer? - Cancer Treatment Reviews
1,2,4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC - ScienceDirect
Figure 2 from EGFR-TKI resistance in NSCLC patients: mechanisms and strategies. | Semantic Scholar
JCM | Free Full-Text | The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer | HTML
Reciprocal relationship between MET amplification and T790M mutation.... | Download Scientific Diagram
Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer? - ScienceDirect
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
Alterations in the PI3K Pathway Drive Resistance to MET Inhibitors in NSCLC Harboring MET Exon 14 Skipping Mutations - Journal of Thoracic Oncology
![PDF] EGFR and c-Met Inhibitors are Effective in Reducing Tumorigenicity in Cancer | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/fb34e0b378ab283ee885fb912c61cc28ae8a288b/3-Figure1-1.png "PDF] EGFR and c-Met Inhibitors are Effective in Reducing Tumorigenicity in Cancer | Semantic Scholar")
PDF] EGFR and c-Met Inhibitors are Effective in Reducing Tumorigenicity in Cancer | Semantic Scholar
